Format

Send to

Choose Destination
Gynecol Oncol. 2010 Nov;119(2):319-24. doi: 10.1016/j.ygyno.2010.08.007.

MTHFR polymorphisms in relation to ovarian cancer risk.

Author information

1
Ob-Gyn Epidemiology Center, Brigham and Women's Hospital, Boston, MA 02115, USA. kterry@partners.org

Abstract

OBJECTIVE:

Folate has been hypothesized to influence carcinogenesis due to its dual role in DNA methylation, which regulates gene expression, and synthesis of purine and thymidylate, which is vital for DNA repair. Thus, we examined ovarian cancer risk in relation to two functional polymorphisms (C677T and A1298C) in the MTHFR gene.

METHODS:

We genotyped the C677T (rs1801133) and A1298C (rs1801131) MTHFR polymorphisms in 1642 cases and 2068 controls from three studies, the New England Case Control Study (NEC), Nurses' Health Study (NHS), and Mayo Clinic Ovarian Cancer Case Control Study (MAY).

RESULTS:

Overall, we observed no association between either SNP and ovarian cancer risk (pooled C677T p(trend)=0.59 and A1298C p(trend)=0.58). Significant associations (C677T p(trend)=0.001, A1298C p(trend)=0.02) between these MTHFR SNPs and serous ovarian cancer risk were observed in the NEC study, but were not replicated in the NHS and MAY studies.

CONCLUSIONS:

MTHFR SNPs C677T and A1298C are not associated with ovarian cancer risk. Our results highlight the need for validation of genetic findings.

PMID:
20817226
PMCID:
PMC2952716
DOI:
10.1016/j.ygyno.2010.08.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center